Firebrick Pharma Limited (FRE.AX)

0.2000 -0.0050 (-2.44%) At close: 02:41PM AEDT

Firebrick Pharma Limited

440 Collins Street
Level 10
Melbourne, VIC 3000
Australia
1300 301 874
https://www.firebrickpharma.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Peter Laurence Molloy BSc, FAICD, MBA	Founder, Exec. Chairman & CEO	324.3k	N/A	1954
Dr. Stephen Francis Goodall MASc, MBA	Founder, COO & Exec. Director	250.43k	N/A	N/A
Mr. Kavi Bekarma B.Sc., C.A.	Chief Financial Officer	N/A	N/A	N/A
Dr. Simon Tucker	Chief Scientific Officer	N/A	N/A	N/A
Ms. Robyn Branigan	Head of Marketing	N/A	N/A	N/A
Prof. Peter Friedland	Chief Medical Officer	N/A	N/A	N/A
Dr. Monique Baldwin	Head of Regulatory Affairs	N/A	N/A	N/A
Mr. Stephen Buckley	Company Sec.	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Firebrick Pharma Limited engages in the development and commercialization of nasal spray treatment for the common cold under the Nasodine name in Australia. The company was incorporated in 2012 and is based in Melbourne, Australia.

Corporate governance

Firebrick Pharma Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.